Drug intelligence / Profile preview

RhuDex

Development stage: Phase 1
Lead developer: MediGene
Modality: Small Molecules
Administration: Oral

Overview

RhuDex is a novel, orally bioavailable, low molecular weight small molecule that acts as an immunomodulating agent by inhibiting the CD80-CD28 costimulatory pathway. It functions as a CD80 antagonist, blocking undesired T-cell activation and exerting anti-inflammatory effects. RhuDex is being developed primarily for autoimmune diseases such as primary biliary cholangitis (PBC) and rheumatoid arthritis. The drug has been evaluated in phase II clinical trials for PBC in patients with inadequate response to ursodeoxycholic acid (UDCA), and has also shown biological activity in early studies for rheumatoid arthritis. Developed by MediGene, RhuDex is not currently approved by any regulatory agency[1][2][3][4][5][6].

Other names: RhuDex choline salt

Targets

CD80 (T-lymphocyte activation antigen CD80)

Beyond the preview

Go deeper on RhuDex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RhuDex.

Explore the full profile